Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Free Cash Flow (2016 - 2025)

Altimmune (ALT) has disclosed Free Cash Flow for 16 consecutive years, with -$11.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 56.13% to -$11.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$66.4 million, a 15.06% increase, with the full-year FY2024 number at -$79.8 million, down 5.26% from a year prior.
  • Free Cash Flow was -$11.9 million for Q3 2025 at Altimmune, up from -$19.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$11.9 million in Q3 2025 to a low of -$27.1 million in Q3 2024.
  • A 5-year average of -$18.8 million and a median of -$18.1 million in 2024 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 444.68% in 2021, then soared 56.13% in 2025.
  • Altimmune's Free Cash Flow stood at -$22.1 million in 2021, then increased by 21.57% to -$17.3 million in 2022, then rose by 4.68% to -$16.5 million in 2023, then decreased by 10.48% to -$18.3 million in 2024, then soared by 34.86% to -$11.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Free Cash Flow are -$11.9 million (Q3 2025), -$19.3 million (Q2 2025), and -$16.8 million (Q1 2025).